SAN
DIEGO, Oct. 31, 2024 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate at several
upcoming investor conferences.
Details of the company's participation are as follows:
- Truist Healthcare Conference
Details: Viking
management will participate in a fireside chat and in 1-on-1
meetings
Conference Date: November 7, 2024
Fireside Chat Timing: 12:30 – 1:00
p.m. Eastern on Thursday, November 7,
2024
Location: New York, NY
- UBS Global Healthcare Conference
Details: Viking
management will participate in 1-on-1 meetings
Conference Dates: November 11-14,
2024
Location: Rancho Palos Verdes,
CA
- Stifel 2024 Healthcare Conference
Details: Viking
management will deliver a corporate presentation and participate in
1-on-1 meetings
Conference Dates: November 18-19,
2024
Presentation Timing: 8:35 – 9:05 a.m.
Eastern on Tuesday, November 19,
2024, webcast available
Location: New York, NY
- Jefferies London Healthcare Conference 2024
Details:
Viking management will deliver a corporate presentation and
participate in 1-on-1 meetings
Conference Dates: November 19-21,
2024
Presentation Timing: 9:00 – 9:25 a.m. GMT on Thursday, November 21, 2024
Location: London, UK
A live webcast of the Stifel presentation may be accessed via a
link on the Viking Therapeutics website in the Investors &
Media section under Webcasts. Additionally, a replay of the
webcast will be available on the Viking website following the
conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. Viking's clinical
programs include VK2735, a novel dual agonist of the glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP) receptors for the potential treatment of various metabolic
disorders. Data from a Phase 1 and a Phase 2 trial evaluating
VK2735 (dosed subcutaneously) for metabolic disorders demonstrated
an encouraging safety and tolerability profile as well as positive
signs of clinical benefit. Concurrently, the company is evaluating
an oral formulation of VK2735 in a Phase 1 trial. Viking is also
developing VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders. The compound successfully
achieved both the primary and secondary endpoints in a recently
completed Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH) and
fibrosis. In a Phase 2a trial for the treatment of
non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C,
patients who received VK2809 demonstrated statistically significant
reductions in LDL-C and liver fat content compared with patients
who received placebo. The company's newest program is
evaluating a series of internally developed dual amylin and
calcitonin receptor agonists (or DACRAs) for the treatment of
obesity and other metabolic disorders. In the rare disease
space, Viking is developing VK0214, a novel, orally available,
small molecule selective thyroid hormone receptor beta agonist for
the potential treatment of X-linked adrenoleukodystrophy
(X-ALD). In a Phase 1b clinical trial in patients
with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was
shown to be safe and well-tolerated, while driving significant
reductions in plasma levels of very long-chain fatty acids (VLCFAs)
and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302292012.html
SOURCE Viking Therapeutics, Inc.
